In this study, 43 % of OSCC had a high CD8-positive TIL infiltrate combined with a PD-L1-positive tumor, matching an “adaptive immune resistance” tumor microenvironment [15] Therefore, these patients could in theory be interesting candidates for neoadjuvant ICIs. This evidence concerns the gene CD8A and neoplasm.